The biology of papillomavirus latency
- PMID: 23341854
- PMCID: PMC3547330
- DOI: 10.2174/1874357901206010190
The biology of papillomavirus latency
Abstract
The presence of viral DNA in the absence of disease has suggested that papillomaviruses, like many other viruses, can exist as latent infections in the skin or other epithelial sites. In animal models, where detailed investigation has been carried out, papillomavirus DNA can be found at sites of previous infection following immune regression, with the site of latent infection being the epithelial basal layer. Such studies suggest that immune surveillance can restrict viral gene expression in the basal and parabasal layers without efficiently suppressing viral genome replication, most probably through the action of memory T-cells in the skin or dermis. Although gradual papillomavirus genome loss appears to occur over time at latent sites, immunosuppression can arrest this, and can lead to an elevation in viral genome copy number in experimental systems. In addition to immune-mediated latency, it appears that a similar situation can be achieved following infection at low virus titres and/or infection at epithelial sites where the virus life cycle is not properly supported. Such silent of asymptomatic infections do not necessarily involve the host immune system and may be controlled by different mechanisms. It appears that virus reactivation can be triggered by mechanical irritation, wounding or by UV irradiation which changes the local environment. Although the duration of papillomavirus latency in humans is not yet known, it is likely that some of the basic principles will resemble those elucidated in these model systems, and that persistence in the absence of disease may be the default outcome for at least some period of time following regression.
Keywords: HPV; Papillomavirus; basal cell; immune regression; immunosuppression.; latency; stem cell.
Figures


Similar articles
-
Latent papillomavirus infections and their regulation.Curr Opin Virol. 2013 Aug;3(4):416-21. doi: 10.1016/j.coviro.2013.06.003. Epub 2013 Jun 29. Curr Opin Virol. 2013. PMID: 23816390 Review.
-
Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression.Virology. 2011 Jun 5;414(2):153-63. doi: 10.1016/j.virol.2011.03.019. Epub 2011 Apr 13. Virology. 2011. PMID: 21492895 Free PMC article.
-
Nuclear Innate Immune DNA Sensor IFI16 Is Degraded during Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus (KSHV): Role of IFI16 in Maintenance of KSHV Latency.J Virol. 2016 Sep 12;90(19):8822-41. doi: 10.1128/JVI.01003-16. Print 2016 Oct 1. J Virol. 2016. PMID: 27466416 Free PMC article.
-
Evidence and impact of human papillomavirus latency.Open Virol J. 2012;6:198-203. doi: 10.2174/1874357901206010198. Epub 2012 Dec 28. Open Virol J. 2012. PMID: 23341855 Free PMC article.
-
The papillomavirus life cycle.J Clin Virol. 2005 Mar;32 Suppl 1:S7-15. doi: 10.1016/j.jcv.2004.12.006. J Clin Virol. 2005. PMID: 15753007 Review.
Cited by
-
Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata.Virol J. 2013 May 1;10:137. doi: 10.1186/1743-422X-10-137. Virol J. 2013. PMID: 23634957 Free PMC article.
-
Development of immunodiagnostic tools for in situ investigation of Ovis aries papillomavirus 3 (OaPV3).Vet Res Commun. 2023 Jun;47(2):641-649. doi: 10.1007/s11259-022-10018-5. Epub 2022 Nov 4. Vet Res Commun. 2023. PMID: 36331789 Free PMC article.
-
Synthesis and Antitumor Activity of Brominated-Ormeloxifene (Br-ORM) against Cervical Cancer.ACS Omega. 2023 Oct 12;8(42):38839-38848. doi: 10.1021/acsomega.3c02277. eCollection 2023 Oct 24. ACS Omega. 2023. PMID: 37901538 Free PMC article.
-
Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life.Papillomavirus Res. 2018 Jun;5:75-79. doi: 10.1016/j.pvr.2018.01.001. Epub 2018 Jan 31. Papillomavirus Res. 2018. PMID: 29355777 Free PMC article.
-
Nested PCR followed by NGS: Validation and application for HPV genotyping of Tunisian cervical samples.PLoS One. 2021 Aug 11;16(8):e0255914. doi: 10.1371/journal.pone.0255914. eCollection 2021. PLoS One. 2021. PMID: 34379683 Free PMC article.
References
-
- Efstathiou S, Preston CM. Towards an understanding of the molecular basis of herpes simplex virus latency. Virus Res. 2005;111(2):108–19. - PubMed
-
- Decman V, Freeman ML, Kinchington PR, Hendricks RL. Immune control of HSV-1 latency. Viral Immunol. 2005; 18(3):466–73. - PubMed
-
- Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol. 2002; 186(1):21–7. - PubMed
-
- Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2000;154(2):127–34. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources